Bridge BioResearch Announces the Granting of US Patent for CD14

26-Jan-2012 - United Kingdom

Bridge Bioresearch PLC (BBR) announces that the company has been granted the US patent for their CD14 molecule indicated for treatment of Diabetes Type 2, obesity, atherosclerosis as well as inflammatory diseases.

Originally acquired from the Spanish Biotech company Mellitus, BBR has continued research in animal models verifying pharmacological properties of the CD14 molecule. BBR has now achieved the granting of the US patent, which according to Mr. Soren Stenderup, CEO of BBR, further strengthens the IP position of CD14 as this complements the already issued European patent.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...